Bio
Novo Nordisk and Korro Bio Collaborate on $530M RNA Editing Deal for Cardiometabolic Diseases
Novo Nordisk, Korro Bio, RNA editing, cardiometabolic diseases, genetic medicines, pharmaceutical partnerships
Nuvation Bio Advances with Pooled Data for ROS1-positive Lung Cancer Treatment, Eyes FDA Submission
Nuvation Bio, ROS1-positive NSCLC, taletrectinib, TRUST-I, TRUST-II, FDA submission, lung cancer treatment
Boundless Bio Implements Strategic Workforce Reduction to Enhance Operational Efficiency
Boundless Bio, workforce reduction, San Diego, operational efficiency, biotech layoffs
Nuvation Bio Halts Development of BET Inhibitor NUV-868 Following Interim Phase 1 Data Review
Nuvation Bio, BET inhibitor, NUV-868, Phase 1 data, oncology drug, safety and efficacy, clinical trials
NGM Bio Secures $122 Million in Funding After Going Private
NGM Bio, funding, private, Column Group, pipeline, orphan diseases
VC Firm Oversees NGM Bio’s $122M Series A Funding After Taking it Private
NGM Bio, The Column Group, Venture Capital, Biotech, Series A Funding
Myricx Bio Secures £90m ($114m) Series A Financing to Advance Novel NMTi ADC Therapeutics
Myricx Bio, Series A Financing, NMTi ADC Therapeutics, Novo Holdings, Lilly, Cancer Treatment
Annovis Bio Reports Promising Phase III Study Results for Buntanetap in Parkinson’s Disease Treatment
Annovis Bio, Buntanetap, Parkinson’s Disease, Phase III Study, Neurodegenerative Disorders, Cognitive Function, Motor Functions, Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
Curie.Bio Raises $380M to Support Early-Stage Biotechs
Curie.Bio, biotech accelerator, venture capital, Series A rounds, early-stage biotechs, Alexis Borisy, Zach Weinberg
Formation Bio Secures $372M Megaround to In-License Over 10 Drugs
Formation Bio, Megaround, In-License, Drugs, Biotech, AI-Focused